Sermorelin
Also known as: GRF 1-29, GHRH (1-29)
At a Glance
Sermorelin is a peptide analog corresponding to GHRH 1–29 (GHRH(1–29)-NH2) studied for its ability to stimulate growth hormone secretion. Early clinical physiology work in healthy subjects examined pharmacokinetics and GH stimulation after different routes of administration. [PMID: 8329825]
⚠️ Research Status: Sermorelin is not an approved medication in many jurisdictions. This page is educational and intentionally does not include protocols/dosing.
Mechanism of Action (TBD)
Acts as a GHRH receptor agonist at pituitary somatotrophs in studied physiology contexts, stimulating GH release. [PMID: 8329825]
Evidence Summary
Pharmacokinetics and GH stimulation (Healthy subjects)
Low Confidence Observational >10 YearsStudy in healthy men reported rapid elimination after intravenous administration and low bioavailability via intranasal delivery in that study context, with measurable GH stimulation. [PMID: 8329825]
Safety & Unknowns
- Endocrine axis effects (GH/IGF-1 and downstream physiology) require careful, citation-backed characterization by indication and population.
- Long-term outcomes and safety depend on clinical context; avoid extrapolating from early physiology studies.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved (verify indication-specific context) |
| European Union (EMA) | Not approved (verify indication-specific context) |
| WADA | Check current list (status may change) |
Related Compounds
- CJC-1295: Another GHRH-related peptide family member often discussed in similar contexts
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added dossier and linked primary literature |